For patients with COPD, mortality higher after admission for pneumonia vs. exacerbation

Among patients with COPD, mortality was higher after hospital admission with pneumonia compared with admission with COPD exacerbation, according to results published in the European Respiratory Journal.
Researchers examined data from the Salford Lung Study, a community-based, randomized, open-label, pragmatic study that evaluated inhaled fluticasone furoate and vilanterol (Breo Ellipta, GlaxoSmithKline) vs. usual care in patients with COPD. They focused on examining mortality after an admission with pneumonia or a severe exacerbation. This analysis included 2,799 patients (mean age, 67 years;

Among patients with COPD, mortality was higher after hospital admission with pneumonia compared with admission with COPD exacerbation, according to results published in the European Respiratory Journal.
Researchers examined data from the Salford Lung Study, a community-based, randomized, open-label, pragmatic study that evaluated inhaled fluticasone furoate and vilanterol (Breo Ellipta, GlaxoSmithKline) vs. usual care in patients with COPD. They focused on examining mortality after an admission with pneumonia or a severe exacerbation. This analysis included 2,799 patients (mean age, 67 years;